Omeros Corp (OMER)
4.40
+0.15
(+3.53%)
USD |
NASDAQ |
Nov 05, 16:00
4.40
0.00 (0.00%)
After-Hours: 18:07
Omeros Research and Development Expense (Annual): 114.87M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 114.87M |
| December 31, 2022 | 112.72M |
| December 31, 2021 | 118.78M |
| December 31, 2020 | 107.61M |
| December 31, 2019 | 106.32M |
| December 31, 2018 | 89.86M |
| December 31, 2017 | 55.60M |
| December 31, 2016 | 50.70M |
| December 31, 2015 | 48.38M |
| Date | Value |
|---|---|
| December 31, 2014 | 47.95M |
| December 31, 2013 | 36.30M |
| December 31, 2012 | 31.92M |
| December 31, 2011 | 23.72M |
| December 31, 2010 | 23.46M |
| December 31, 2009 | 16.93M |
| December 31, 2008 | 17.85M |
| December 31, 2007 | 15.92M |
| December 31, 2006 | 20.53M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
106.32M
Minimum
2019
118.78M
Maximum
2021
112.06M
Average
112.72M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Harrow Inc | 6.652M |
| Amphastar Pharmaceuticals Inc | 73.74M |
| PetIQ Inc | -- |
| Alector Inc | 192.12M |
| Outset Medical Inc | 57.31M |